Difficulties and advancements in developing drugs for the treatment of dengue fever

Christian G. Noble, Pei Yong Shi

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral pathogen in humans. There are no drugs available to treat dengue virus infection. Here, we discuss the strategies and challenges to develop dengue drugs. Treating the disease pathology is hindered by a lack of understanding of the disease progression and the causes of disease symptoms such as vascular leakage. Most drug-discovery efforts have concentrated on viral targets, which have their own particular challenges. Despite various challenges, great progresses have been made towards the development of dengue therapy. Ultimately, the only way to know whether a direct-acting antiviral will be a viable approach for treating dengue patients is to test safe compounds with demonstrated antiviral activity in human trials.

Original languageEnglish (US)
Pages (from-to)947-949
Number of pages3
JournalExpert Opinion on Orphan Drugs
Volume1
Issue number12
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Keywords

  • Antiviral
  • Dengue virus
  • Drug discovery
  • Flavivirus
  • Inhibitor

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Difficulties and advancements in developing drugs for the treatment of dengue fever'. Together they form a unique fingerprint.

  • Cite this